A Waukesha County deputy is battling a "rare, aggressive cancer." Steve Lyles has been with the department for nearly 20 ...

Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) data, helping to improve understanding of the lesions that occur in chronic ...

In a remarkable journey of resilience, 12-year-old dancer Lauren Torres has defied the odds after undergoing a life-saving ...

Metastatic papillary renal cancer has poor outcomes, and new treatments are needed. There is a strong rationale for investigating the combination of mesenchymal epithelial transition receptor (MET) ...

The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

Due to the ongoing shortage of BCG, gemcitabine has been increasingly used for first-line NMIBC therapy. N-803’s ability to activate natural killer and CD8+ T cells, thus the innate immune system, to ...

Despite guidelines addressing overdetection, no significant declines are seen; emphasis on active surveillance approaches is ...

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...

with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1). Mayo Clinic will present additional updated early results in a poster presentation of an independent, retrospective real-world ...

Noah S. Kalman, MD, MBA, discusses the evolving role of molecular and genetic testing in thyroid cancer management.

The following is a summary of “Therapeutic outcomes and safety of radiofrequency ablation for primary papillary thyroid carcinoma: A game-changing meta-analysis,” published in the February 2025 issue ...